Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease

Akira Monji, Masashi Takita, Takaaki Samejima, Toshihiro Takaishi, Kazuhito Hashimoto, Hiroyuki Matsunaga, Mariko Oda, Yasuhisa Sumida, Yoshito Mizoguchi, Takahiro Kato, Hideki Horikawa, Shigenobu Kanba

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Objective: The aim of this study was to investigate the effects of yokukansan (YKS) on the behavioral and psychological symptoms of dementia (BPSD) in elderly patients with Alzheimer's disease (AD). Methods: Fifteen patients with AD (mean age: 80.2 ± 4.0 years) participated in the study. The Mini-Mental State Examination (MMSE) was used for the assessment of cognitive function. BPSD were evaluated using the Neuropsychiatric Inventory (NPI). The Barthel Index was used for the assessment for the activities of daily living (ADL). The treatment with YKS along with sulpiride, a dopamine D2 selective antipsychotic, was performed for 12 weeks. Results: Fourteen patients completed the trial. After the 12 weeks of treatment with YKS, significant improvement of the mean NPI score was observed while no significant improvement was observed in the control group. The average dose of sulpiride at the end of the present study was less in the YKS group than in the control group. The MMSE results did not change either in the YKS group or in the control group. The Barthel Index did not significantly change either in the YKS group or in the control group. No serious adverse effects were noted. Conclusions: Twelve weeks of the YKS treatment significantly improved BPSD with less antipsychotics in elderly patients with AD. The YKS treatment did not cause any cognitive decline or ADL decline and no serious adverse effects were noted. The present study suggests that YKS is beneficial for the treatment of BPSD and that it can possibly reduce the doses of antipsychotics required for the treatment of BPSD. Further studies with larger patient populations using a double-blind placebo-controlled design should be performed.

Original languageEnglish
Pages (from-to)308-311
Number of pages4
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume33
Issue number2
DOIs
Publication statusPublished - Mar 17 2009

Fingerprint

Behavioral Symptoms
Dementia
Alzheimer Disease
Psychology
Antipsychotic Agents
Sulpiride
Control Groups
Activities of Daily Living
Therapeutics
Yi-Gan San
Equipment and Supplies
Cognition
Dopamine
Placebos

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Biological Psychiatry

Cite this

Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. / Monji, Akira; Takita, Masashi; Samejima, Takaaki; Takaishi, Toshihiro; Hashimoto, Kazuhito; Matsunaga, Hiroyuki; Oda, Mariko; Sumida, Yasuhisa; Mizoguchi, Yoshito; Kato, Takahiro; Horikawa, Hideki; Kanba, Shigenobu.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 33, No. 2, 17.03.2009, p. 308-311.

Research output: Contribution to journalArticle

Monji, A, Takita, M, Samejima, T, Takaishi, T, Hashimoto, K, Matsunaga, H, Oda, M, Sumida, Y, Mizoguchi, Y, Kato, T, Horikawa, H & Kanba, S 2009, 'Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, no. 2, pp. 308-311. https://doi.org/10.1016/j.pnpbp.2008.12.008
Monji, Akira ; Takita, Masashi ; Samejima, Takaaki ; Takaishi, Toshihiro ; Hashimoto, Kazuhito ; Matsunaga, Hiroyuki ; Oda, Mariko ; Sumida, Yasuhisa ; Mizoguchi, Yoshito ; Kato, Takahiro ; Horikawa, Hideki ; Kanba, Shigenobu. / Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2009 ; Vol. 33, No. 2. pp. 308-311.
@article{6698ba1478e941499908c7ea3ed28895,
title = "Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease",
abstract = "Objective: The aim of this study was to investigate the effects of yokukansan (YKS) on the behavioral and psychological symptoms of dementia (BPSD) in elderly patients with Alzheimer's disease (AD). Methods: Fifteen patients with AD (mean age: 80.2 ± 4.0 years) participated in the study. The Mini-Mental State Examination (MMSE) was used for the assessment of cognitive function. BPSD were evaluated using the Neuropsychiatric Inventory (NPI). The Barthel Index was used for the assessment for the activities of daily living (ADL). The treatment with YKS along with sulpiride, a dopamine D2 selective antipsychotic, was performed for 12 weeks. Results: Fourteen patients completed the trial. After the 12 weeks of treatment with YKS, significant improvement of the mean NPI score was observed while no significant improvement was observed in the control group. The average dose of sulpiride at the end of the present study was less in the YKS group than in the control group. The MMSE results did not change either in the YKS group or in the control group. The Barthel Index did not significantly change either in the YKS group or in the control group. No serious adverse effects were noted. Conclusions: Twelve weeks of the YKS treatment significantly improved BPSD with less antipsychotics in elderly patients with AD. The YKS treatment did not cause any cognitive decline or ADL decline and no serious adverse effects were noted. The present study suggests that YKS is beneficial for the treatment of BPSD and that it can possibly reduce the doses of antipsychotics required for the treatment of BPSD. Further studies with larger patient populations using a double-blind placebo-controlled design should be performed.",
author = "Akira Monji and Masashi Takita and Takaaki Samejima and Toshihiro Takaishi and Kazuhito Hashimoto and Hiroyuki Matsunaga and Mariko Oda and Yasuhisa Sumida and Yoshito Mizoguchi and Takahiro Kato and Hideki Horikawa and Shigenobu Kanba",
year = "2009",
month = "3",
day = "17",
doi = "10.1016/j.pnpbp.2008.12.008",
language = "English",
volume = "33",
pages = "308--311",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease

AU - Monji, Akira

AU - Takita, Masashi

AU - Samejima, Takaaki

AU - Takaishi, Toshihiro

AU - Hashimoto, Kazuhito

AU - Matsunaga, Hiroyuki

AU - Oda, Mariko

AU - Sumida, Yasuhisa

AU - Mizoguchi, Yoshito

AU - Kato, Takahiro

AU - Horikawa, Hideki

AU - Kanba, Shigenobu

PY - 2009/3/17

Y1 - 2009/3/17

N2 - Objective: The aim of this study was to investigate the effects of yokukansan (YKS) on the behavioral and psychological symptoms of dementia (BPSD) in elderly patients with Alzheimer's disease (AD). Methods: Fifteen patients with AD (mean age: 80.2 ± 4.0 years) participated in the study. The Mini-Mental State Examination (MMSE) was used for the assessment of cognitive function. BPSD were evaluated using the Neuropsychiatric Inventory (NPI). The Barthel Index was used for the assessment for the activities of daily living (ADL). The treatment with YKS along with sulpiride, a dopamine D2 selective antipsychotic, was performed for 12 weeks. Results: Fourteen patients completed the trial. After the 12 weeks of treatment with YKS, significant improvement of the mean NPI score was observed while no significant improvement was observed in the control group. The average dose of sulpiride at the end of the present study was less in the YKS group than in the control group. The MMSE results did not change either in the YKS group or in the control group. The Barthel Index did not significantly change either in the YKS group or in the control group. No serious adverse effects were noted. Conclusions: Twelve weeks of the YKS treatment significantly improved BPSD with less antipsychotics in elderly patients with AD. The YKS treatment did not cause any cognitive decline or ADL decline and no serious adverse effects were noted. The present study suggests that YKS is beneficial for the treatment of BPSD and that it can possibly reduce the doses of antipsychotics required for the treatment of BPSD. Further studies with larger patient populations using a double-blind placebo-controlled design should be performed.

AB - Objective: The aim of this study was to investigate the effects of yokukansan (YKS) on the behavioral and psychological symptoms of dementia (BPSD) in elderly patients with Alzheimer's disease (AD). Methods: Fifteen patients with AD (mean age: 80.2 ± 4.0 years) participated in the study. The Mini-Mental State Examination (MMSE) was used for the assessment of cognitive function. BPSD were evaluated using the Neuropsychiatric Inventory (NPI). The Barthel Index was used for the assessment for the activities of daily living (ADL). The treatment with YKS along with sulpiride, a dopamine D2 selective antipsychotic, was performed for 12 weeks. Results: Fourteen patients completed the trial. After the 12 weeks of treatment with YKS, significant improvement of the mean NPI score was observed while no significant improvement was observed in the control group. The average dose of sulpiride at the end of the present study was less in the YKS group than in the control group. The MMSE results did not change either in the YKS group or in the control group. The Barthel Index did not significantly change either in the YKS group or in the control group. No serious adverse effects were noted. Conclusions: Twelve weeks of the YKS treatment significantly improved BPSD with less antipsychotics in elderly patients with AD. The YKS treatment did not cause any cognitive decline or ADL decline and no serious adverse effects were noted. The present study suggests that YKS is beneficial for the treatment of BPSD and that it can possibly reduce the doses of antipsychotics required for the treatment of BPSD. Further studies with larger patient populations using a double-blind placebo-controlled design should be performed.

UR - http://www.scopus.com/inward/record.url?scp=60049099127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60049099127&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2008.12.008

DO - 10.1016/j.pnpbp.2008.12.008

M3 - Article

C2 - 19138715

AN - SCOPUS:60049099127

VL - 33

SP - 308

EP - 311

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 2

ER -